Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Clarient, Inc. (“Clarient” or the “Company”) (Nasdaq: CLRT) concerning the Company’s receipt of an offer to purchase all outstanding common shares of the Company for $5 per share and each outstanding preferred share for $20 by GE Healthcare, Inc. The proposed offer is valued at approximately $580 million and is expected to close in late 2010 or early 2011.
The investigation is focused on the potential unfairness of the transaction price to Clarient shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among Clarient Board members. Stockholders holding approximately 47% of Clarient’s current outstanding voting stock have agreed to tender their shares in the proposed offer, about 35% of which is held by insiders and major shareholders of the Company. Additionally, according to Yahoo! Finance, at least one analyst has set a target price of $6 for Clarient stock.
If you are interested in discussing your rights as a Clarient shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our web site at
. Attorney advertising. Prior results do not guarantee similar outcomes.